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Abstract
Complex I deficiency is a common cause of mitochondrial disease, resulting from mutations in genes encoding structural
subunits, assembly factors or defects in mitochondrial gene expression. Advances in genetic diagnostics and sequencing
have led to identification of several variants in NUBPL (nucleotide binding protein-like), encoding an assembly factor of
complex I, which are potentially pathogenic. To help assign pathogenicity and learn more about the function of NUBPL,
amino acid substitutions were recreated in the homologous Ind1 protein of the yeast model Yarrowia lipolytica. Leu102Pro
destabilized the Ind1 protein, leading to a null-mutant phenotype. Asp103Tyr, Leu191Phe and Gly285Cys affected complex I
assembly to varying degrees, whereas Gly136Asp substitution in Ind1 did not impact on complex I levels nor
dNADH:ubiquinone activity. Blue-native polyacrylamide gel electrophoresis and immunolabelling of the structural subunits
NUBM and NUCM revealed that all Ind1 variants accumulated a Q module intermediate of complex I. In the Ind1 Asp103Tyr
variant, the matrix arm intermediate was virtually absent, indicating a dominant effect. Dysfunction of Ind1, but not
absence of complex I, rendered Y. lipolytica sensitive to cold. The Ind1 Gly285Cys variant was able to support complex I
assembly at 28◦C, but not at 10◦C. Our results indicate that Ind1 is required for progression of assembly from the Q module
to the full matrix arm. Cold sensitivity could be developed as a phenotype assay to demonstrate pathogenicity of NUBPL
mutations and other complex I defects.
Introduction
Defects in respiratory chain function underlie a large share of
mitochondrial disorders, of which a third are due to complex I
deficiency (OMIM 252010) (1–3). Clinical presentations such as
Leigh syndrome usually occur in infancy or early adulthood.
Symptoms include skeletal muscle myopathy, cardiomyopathy,
hypotonia, stroke, ataxia and lactic acidosis (3,4). Human com-
plex I has 44 different structural subunits, of which 37 are
encoded in the nuclear genome and 7 in the mitochondrial
genome (5). Disease-causing mutations have been identified in
27 out of 44 structural genes. However, this only provides a
diagnosis for about 50% of cases, as complex I deficiency may
also be caused by mutations in assembly factors, tRNAs and
other genes for mitochondrial gene expression or mitochondrial
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DNA maintenance (2,6). Assembly factors are defined as pro-
teins which are required for the correct assembly and function
of complex I but are not present in the mature structure. So
far, 16 assembly proteins have been identified for complex I,
and disease-causing mutations have been found in 11 of those
(3,7). Particularly, advances in genome sequencing have led to
the identification of several novel genes affecting complex I
function, providing a genetic diagnosis for patients with these
rare inheritable conditions.
The complex I assembly factor NUBPL (nucleotide binding
protein-like) was first identified in the aerobic yeast Yarrowia
lipolytica where it was named Ind1 (iron–sulfur protein required
for NADH dehydrogenase) (8). Genomic deletion of IND1 resulted
in a major decrease in complex I, to approximately 28% of wild-
type levels, but no effect on other respiratory complexes. Ind1
has been proposed to insert iron–sulfur (FeS) clusters in complex
I based on its homology to the cytosolic FeS cluster assembly
factors Nbp35 and Cfd1, corresponding to NUBP1 and NUBP2,
respectively, in human (9). However, it should be noted that
Ind1 is not essentially required for complex I in Y. lipolytica,
and it would therefore only have an auxiliary role in cofactor
assembly.
Phylogenetic analysis showed that the IND1 gene is present
in almost all eukaryotes, and closely matches the distribution
of complex I (8). RNAi knockdown of NUBPL in human HeLa cells
led to a specific decrease in complex I, as well as accumulation of
assembly intermediates (10).Moreover,mutations inNUBPLwere
identified by exome sequencing in clinically described cases of
complex I deficiency (1,11,12). Recently,NUBPLwas found among
191 genes that are essential for oxidative phosphorylation in a
genome-wide CRISPR/Cas9 screen of human leukemia K562 cells
(13). The IND1 homologue in the model plant Arabidopsis thaliana
is also required for complex I assembly (14). Combined, these
studies show that NUBPL has an evolutionary conserved func-
tion in complex I assembly, but its precise molecular function
remains to be demonstrated.
So far, 13 cases (in 11 families) with likely clinically relevant
mutations in NUBPL have been reported or newly diagnosed
(Table 1). Patients display various symptoms within the broad
spectrum ofmitochondrial disorders, includingmotor problems,
increased lactate levels and some degree of complex I deficiency
(1,11,12). In addition, NUBPL patients show a distinct magnetic
resonance imaging pattern with abnormalities of the cerebel-
lar cortex, deep cerebral white matter and corpus callosum
(11). Genetic analyses revealed that all but one patient have
inherited an intronic mutation in one copy of NUBPL, c.815-
27T>C, together with a likely deleterious mutation in the other
copy of the gene (Table 1). The c.815-27T>C mutation affects
a splicing branch site in intron 9, leading to aberrant mRNA
splicing (15). Approximately 30% of wild-type NUBPL transcript
remains, but two mis-spliced transcripts are also produced. One
of these disappears by nonsense mediated decay. The other
mis-spliced transcript lacks exon 10, leading to Asp273Gln, a
frameshift and then a premature stop codon. The predicted
protein product, p.(D273Qfs*31), is unstable, and NUBPL protein
is almost undetectable in patient fibroblasts (15). The c.815-
27T>C variant is often co-inherited with the missense variant
c.G166>A (p.Gly56Arg), which, on its own, is not thought to be
pathogenic (15), and is absent in at least two cases (Table 1,
patient 2 and siblings 10 and 11). Recently, a clinical case of
hereditary bilateral striatal necrosis was potentially attributed
to biallelic missense variants in NUBPL, but neither the branch
site mutation nor c.G166>Awas found (Table 1, patient 9). It was
suggested that this case represents the less severe end of the
spectrum of NUBPL dysfunction, compared with the reported
cases with the branch site mutation (16).
The haploid yeast Y. lipolytica has been used extensively in
biotechnology, but it has also been developed as a model organ-
ism to study complex I biology (17–21). This has been necessary
because the usual yeast model Baker’s yeast, Saccharomyces cere-
visae, does not have complex I. The D273Qfs*31 variant of NUBPL
was recreated in the Ind1 protein of Y. lipolytica, which confirmed
that the altered protein was unable to support the assembly of
complex I (22). Here, we compare five missense variants in the
NUBPL gene, two of which are newly identified in patients, in an
effort to assign pathogenicity and to enhance our understanding
of the molecular function of NUBPL/Ind1. The resulting pro-
tein variants were tested in Y. lipolytica for protein stability and
complex I levels, oxidoreductase activity and assembly inter-
mediates. Together, the results indicate pathogenicity of four
missense mutations and reveal that ind1 mutants are sensitive
to low temperature.
Results
Selection of NUBPL mutations for analysis in Y. lipolytica
Thirteen cases of mitochondrial disorders associated with
mutations in NUBPL have been published or were otherwise
known to us (Table 1). Mutations that result in frameshifts,
insertions or deletions (patients 1–4 and 7) are almost certainly
deleterious but are unlikely to shed light on the molecular
function of NUBPL. Instead, we focused on assessing the
functional impact of patient mutations resulting in a single
amino acid change at a conserved position, such as Leu104Pro
(L104P,patients 9, 10, 11 and 12),Asp105Tyr (D105Y,patients 5 and
6), Leu193Phe (L193F, patient 8) and Gly287Cys (G287C, patient
13).Manymoremissense variants inNUBPLhave beenuncovered
by large-scale exome sequencing (gnomad.broadinstitute.org), of
which Asn198Tyr and Val182Ala occur at a relatively high allele
frequency (Table 2). While Asn198 and Val182 are not conserved
in Y. lipolytica Ind1, the NUBPL Gly138Asp (G138D) variant with an
allele frequency of 6.73× 10-4 does affect a conserved amino acid,
corresponding to Gly136 in Y. lipolytica Ind1, and was included in
this study. G138D is predicted to be damaging to NUBPL (Table 2)
and has been found in two Parkinson’s disease patients (P. Eis
and E. Hatchwell, personal communication).
L104P and D105Y affect residues in the highly conserved
Switch I motif (Fig. 1A), which is involved in ATP hydrolysis;
L193F affects a residue just outside the Mrp family signature
motif; and G287C introduces an additional cysteine to the C-
terminus, which may create an unwanted disulphide bridge.
G138 is not in a conserved motif, but the introduction of a
negatively charged Asp could affect protein folding. The corre-
sponding amino acids in the Ind1 protein of Y. lipolytica were
identified by alignment using Clustal Omega (Fig. 1A; Table 3),
and this amino acid numbering is used throughout the study.
A homology model of Ind1 was made, and the positions of the
substituted amino acids are indicated in Fig. 1B.
Protein stability in Ind1 variants
In order to study the biochemical and physiological effects of the
amino acid changes, site-directed mutations were introduced
into a plasmid carrying the IND1 gene under the control of its
native promoter and transformed into Y. lipolytica ind1 cells,
a GB10 strain with a genomic deletion of the IND1 gene (8).
The plasmid contains a chromosomal ARS/CEN region which is
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Table 1. Overview of mutations in NUBPL (NG_028349.1) associated with complex I deficiency or mitochondrial disease (OMIM 252010)
Patient Coding DNA Protein Site Paternal or maternal Reference
1 c.166G>A p.(Gly56Arg) Exon 2 Paternal (1,15)
c.815-27T>Ca p.(Asp273Glnfs*31) Intron 9 Paternal
240 kb deletion Exons 1–4 Maternal
137 kb duplication Exon 7 Maternal
2 c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Paternal (12)
c.205_206delGT p.(Val69Tyrfs*80) Exon 2 Maternal
3b c.166G>A p.(Gly56Arg) Exon 2 N/A (11)
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 N/A
4 c.166G>A p.(Gly56Arg) Exon 2 Paternal (11)
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Paternal
c.667_668insCCTTGTGCTG p.(Glu223Aspfs*4) Exon 8 Maternal
5,6 c.166G>A p.(Gly56Arg) Exon 2 Paternal (11)
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Paternal
c.313G>T p.(Asp105Tyr) Exon 4 Maternal
7 c.166G>A p.(Gly56Arg) Exon 2 Paternal (11)
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Paternal
c.693+1G>A p.? Intron 8 Maternal
8 c.579A>C p.(Leu193Phe) Exon 7 Paternal (11)
c.166G>A p.(Gly56Arg) Exon 2 Maternal
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Maternal
9 c.311T>C p.(Leu104Pro) Exon 4 Paternal (16)
c.287A>T p.(Asp96Val) Exon 3 Maternal
10, 11 c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Paternal Unpublished clinical casesc
c.311T>C p.(Leu104Pro) Exon 4 Maternal
12 c.166G>A p.(Gly56Arg) Exon 2 Maternal Unpublished clinical casec
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 Maternal
c.311T>C p.(Leu104Pro) Exon 4 Paternal
13 c.166G>A p.(Gly56Arg) Exon 2 N/A Unpublished clinical casec
c.815-27T>C p.(Asp273Glnfs*31) Intron 9 N/A
c.859G>T p.(Gly287Cys) Exon 10 N/A
aThe paternal c.166G>A mutation and the maternal exon deletions/duplication were identified by exome sequencing and a microarray, respectively (1), but further
analysis identified the c.815-27T>C splice site mutation in the paternal allele (15).
bKevelam et al. (11) could not confirm whether the mutations were homozygous or hemizygous because no parental DNA or fibroblasts were available for study.
However, given the other cases, it is possible that another mutation in NUBPL is present to give a compound heterozygous situation.
cClinical features for complex-I-deficiency patients 10, 11 and 12 have not been published (V. Kimonis, personal communication), but the mutations have been
previously reported (41,42). Clinical features and mutations for patient 13 have not been published (H. Prokisch, personal communication).
Table 2. Allele frequencies and PolyPhen-2 scores of NUBPL missense variants
Protein variant 1-letter code Allele count Total alleles Allele frequency Conserved in Y. lip PolyPhen-2
p.(Asn198Thr) N198T 1207 276 746 4.36 × 10-3 No 0.888
p.(Asp273Glnfs*31) 1000 276 338 3.62 × 10-3 N/A N/A
due to c.815-27T>C
p.(Val182Ala) V182A 730 276 900 2.64 × 10-3 No 0.923
p.(Gly26Val) G26V 265 149 738 1.77 × 10-3 No 0.041
p.(His229Tyr) H229Y 349 276 920 1.26 × 10-3 No 0.754
p.(Gly138Asp) G138D 185 275 070 6.73 × 10-4 Yes 0.999
p.(Ser128Asn) S128N 57 264 100 2.16 × 10-4 No 0.000
p.(Leu104Pro) L104P 40 276 904 1.45 × 10-4 Yes 1.000
p.(Lys59Arg) K59R 39 276 958 1.41 × 10-4 No 0.187
p.(Gly56Arg) G56R 38 276 640 1.37 × 10-4 No 0.998
p.(Asp105Tyr) D105Y 6 276 922 2.17 × 10-5 Yes 1.000
p.(Asp96Val) D96V N/A N/A N/A No 0.714
p.(Leu193Phe) L193F N/A N/A N/A Yes 1.000
p.(Gly287Cys) G287C N/A N/A N/A Yes 1.000
Allele frequency data from gnomAD (http://gnomad.broadinstitute.org/) for the most commonly occurring missense mutations in NUBPL, as well as the clinically
relevant variants listed in Table 1. A PolyPhen-2 score close to 1 indicates that the amino acid change is “probably damaging”.
maintained at ∼1 copy per cell. The GB10 strain was engineered
to contain the NDH2i gene, encoding an alternative NADH dehy-
drogenase targeted to the matrix side of the inner mitochon-
drial membrane, which bypasses the essential requirement of
respiratory complex I in Y. lipolytica (23). The previously reported
variant Ind1 protein N271Qfs*31, recapitulating the effect of the
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Figure 1. Amino acid substitutions in NUBPL and their position in the homologous Ind1 protein in Y. lipolytica. (A) Alignment of amino acid sequences of human (Hs)
NUBPL (NP_079428.2) and Y. lipolytica (Yl) Ind1 (XP_501064.1) using Clustal Omega and Boxshade for colouring. Amino acid changes that are investigated in this study
are indicated with red boxes. Amino acid changes associated with clinical cases but which are not conserved in Yarrowia are indicated with blue boxes. Positions D273
in NUBPL and N271 in Ind1 are indicated with a green box. The start of the mature N-terminus is indicated with a triangle. The Walker A motif (P-loop), Switch I,
Mrp family signature (ProSite entry PS01215) and CxxC motif are indicated. (B) Homology model of Ind1 using IntFOLD server using template 3vx3A.pdb (HypB from
Thermococcus kodakarensis KOD1). Amino acid residues that were substituted in this study are indicated with red spheres.
c.815-27T>C branch-site mutation in NUBPL, was included for
comparison (22).
Mitochondrial membranes of each strain were isolated and
subjected to Western blot analysis to visualize Ind1 protein
levels. The D103Y, G136D, L191F and G285C variants displayed
levels of Ind1 protein similar to ind1 + IND1 (henceforth referred
to as complemented wild type, cWT) (Fig. 2A). The L102P substi-
tution resulted in lower levels of Ind1 protein, to approximately
45% of cWT levels. The decrease in L102P protein was similar
to that seen in N271Qfs*31. Antibodies against aconitase (Aco1)
and subunit 2 of complex II (Sdh2) were used as a loading control
and to confirm that other FeS cluster binding proteins are not
affected (Fig. 2A).
To rule out that lower amounts of the Ind1L102P protein were
due to decreased transcript levels, expression of IND1 was
assessed by reverse transcription–polymerase chain reaction
(RT-PCR) (Fig. 2B). While this technique is not quantitative, at
low cycle numbers, major differences in transcript levels are
easily detected. Normal levels of IND1 transcript in the L102P
variant indicated that the protein undergoes post-translational
degradation. In order to further investigate the effect of L102P
on protein stability, Ind1 and Ind1L102P were expressed in E. coli.
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Table 3. Summary of human and Yarrowia variants analyzed in this study
H. sapiens amino acid variant Y. lipolytica amino acid variant Protein stability Complex I levels Assembly intermediates Growth in cold
L104P L102P Decreased Severely decreased NUBM and NUCM Impaired
D105Y D103Y Normal Severely decreased NUBM and NUCM Impaired
G138D G136D Normal Normal NUCM Normal
L193F L191F Normal Slightly decreased NUCM Impaired
G287C G285C Normal Normal NUCM Impaired
D273Qfs*31 N271Qfs*31 Decreased Severely decreased NUBM and NUCM Impaired
Figure 2. Expression of variant Ind1 proteins in Y. lipolytica. (A) Protein blot analysis of Ind1 in mitochondrial membranes from strains expressing wild-type IND1 (cWT)
and the indicated protein variants, in the ind1 background. The N271Qfs*31 protein is of lower molecular weight due to truncation of the C-terminus by 11 amino
acids. Antibodies against the mitochondrial protein aconitase (Aco1) and subunit 2 of succinate dehydrogenase (Sdh2) were used to confirm equal protein loading and
stability of these FeS cluster proteins in ind1mutants. (B) Transcript levels of IND1L102P comparedwithwild-type IND1 by RT-PCR.A PCR reaction for PYC1 (YALI0C24101g),
containing an intron, showed that the cDNA samples were free from genomic DNA and equal in cDNA content. ACTIN1 was used as an additional control for equal
amounts of cDNA template. (C) Solubility of wild-type Ind1 and Ind1L102P protein expressed in E. coli. Total protein extract (T) was sonicated and centrifuged to give
insoluble pellet (P) and soluble supernatant (SN). Gels were stained with Instant Blue (left panels) or immunolabelled for Ind1 (right panels).
Separation of soluble and insoluble fractions showed that all
of the Ind1L102P protein is found in the insoluble pellet fraction,
whilst most of the normal Ind1 protein can be found in the
soluble fraction.This suggests that the L102P substitution causes
protein misfolding, which would result in its degradation by
proteases. Overall these data show that, with the exception of
L102P, the selected amino acid substitutions in Ind1 do not affect
protein stability.
Ind1 variants L102P, D103Y and L191F have
significantly decreased levels of complex I
It has previously been shown that cells lacking IND1 have
approximately 28% of fully active complex I compared with wild
type (8). To investigate the effect of the amino acid variants in
Ind1 on complex I, mitochondrial membranes were separated
by blue-native polyacrylamide gel electrophoresis (BN-PAGE)
to resolve the respiratory complexes. Incubation of the gel
with NADH and nitro-blue tetrazolium (NBT) reveals NADH
dehydrogenase activities, which is used as a proxy to estimate
complex I levels (24). In cells expressing the Ind1 variants
L102P and D103Y, complex I was strongly decreased, similar
to the levels in the ind1 mutant (empty vector control, e.v.)
and N271Qfs*31 (Fig. 3A). The L191F substitution resulted in a
minor decrease in complex I, whereas G136D and G285C were
indistinguishable from cWT. For comparison, a knockout strain
of the NUBM subunit of complex I (nubm) displayed no complex
I activity, in agreement with the FMN cofactor of NUBM being
the site of NADH oxidation. Another complex I mutant, where a
key catalytic residue of the NUCM subunit has been substituted
(Y144F) (25), displayed complex I levels similar to cWT. This
is consistent with a mutation that affects catalysis but not
assembly of complex I. Complex V levels were unaffected by
mutations in IND1 (Fig. 3A, lower Coomassie-stained band).
To measure the oxidoreductase activity of the matrix arm
of complex I, two different spectrophotometric assays were
used. Electron transfer from NADH to the artificial electron
acceptor hexaammineruthenium(III) chloride (HAR) involves
only the primary electron acceptor FMN bound to the NUBM
subunit of complex I and, like NADH:NBT staining, serves as
a proxy for complex I content. The L102P, D103Y, L191F and
N271Qfs*31 variants showed a significant decrease inNADH:HAR
activity, whereas G136D and G285C were similar to cWT (Fig. 3B,
Table S1).
To assess NADH:ubiquinone oxidoreductase activity, electron
transfer from deamino-NADH (dNADH) to n-decylubiquinone
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Figure 3. Complex I levels and oxidoreductase activities in Ind1 variants. (A) Complex I levels shown by in-gel NADH:NBT staining of mitochondrial membranes from
ind1 producing wild-type IND1 (cWT) and the indicated protein variants, compared with two characterized complex I mutants, nubm and nucm + NUCMY144F.
(B) NADH:HAR and (C) dNADH:DBQ oxidoreductase activity in mitochondrial membranes from the indicated strains. Bars represent the mean ± SE (n = 3 biological
replicates). * p<0.05, ** p<0.01 (two-sample t-test). Numerical values are given in Table S1.
(DBQ) was measured, encompassing all cofactors in the matrix
arm of complex I. A significant decrease in electron transfer
was seen with the L102P, D103Y, L191F and N271Qfs*31 variants,
but not in G136D and G285C (Fig. 3C, Table S1). The nucm
+ NUCMY144F mutant had low dNADH:DBQ activity (Table S1),
despite wild-type levels of fully assembled complex I (Fig. 3A).
Comparison of dNADH:DBQ activity between the Ind1 variants
and nucm + NUCMY144F shows that in the Ind1 variants there
is still substantial activity remaining. For the Ind1 variants, the
NADH:HAR activities correspond with those of dNADH:DBQ,
suggesting that all the complex I present is enzymatically
active.
Taken together, the data from three different methods are in
agreement and indicate that the L102P and D103Y substitutions
in Ind1 cause a defect in complex I assembly of similar severity
as IND1 deletion. The L191F substitution caused amild decrease,
whereas G136D and G285C appeared to have no significant effect
on complex I levels under standard growth conditions.
All ind1 mutants accumulate a Q module assembly
intermediate
In human cell lines depleted of NUBPL, a subcomplex represent-
ing part of the membrane arm was observed (10). Similarly, the
Arabidopsis indh mutant had a membrane arm assembly inter-
mediate, but no full-size complex I (14). To investigate complex
I assembly in Y. lipolytica cells lacking Ind1, the ind1 strain
was compared with mutant strains of different subunits of the
matrix arm of complex I, nubm, nucm and nukm. NUBM is
the homologue of the human NDUFV1 protein (bovine 51-kDa
subunit) in the N module. NUCM (human NDUFS2, bovine 49
kDa) and NUKM (human NDUFS7, bovine PSST) are in the Q
module (Fig. 4A). In the ind1mutant, the protein levels of NUBM
are slightly decreased, but the levels of NUCM are not affected
(Fig. 4B). Thus, compared with the decreased levels of complex I
in ind1, NUBM and NUCM are imported into the mitochondrial
matrix, but the majority is not assembled. Decreased levels of
NUBM are also seen in the nucm and nukm mutants.
Mitochondrial membranes were isolated from cWT, ind1,
nubm, nucm and nukm, and the respiratory complexes
were separated by BN-PAGE, followed by in-gel activity staining
and Western blot analysis with antibodies against NUBM and
NUCM. This confirmed the lack of complex I in the nucm
and nukm mutants (Fig. 4C). In the nubm mutant, NUCM
antibodies detected a weak signal around∼1MD (Fig. 4C, bottom
panel), likely corresponding to a small amount of complex that
lacks NUBM. NADH:NBT activity staining did not detect any
full-size complex I in nubm, consistent with NUBM being the
site of NADH oxidation. At longer exposure times to visualize
assembly intermediates, a subcomplex of approximately 500
kDa containing both NUBM and NUCM was seen in the ind1
mutant, which was also found in cWT (Fig. 4C). This subcomplex
is likely to represent the full matrix arm of complex I (26). An
additional assembly intermediate containing NUCM, but not
NUBM, was found at approximately 160 kDa. This intermediate
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/21/3697/5048951 by U
niversity of East Anglia user on 02 N
ovem
ber 2018
Human Molecular Genetics, 2018, Vol. 27, No. 21 3703
Figure 4. Complex I assembly in ind1 compared with deletion mutants of other subunits. (A) Diagram of complex I showing the position of NUBM in the N module
and NUCM and NUKM in the Q module of the matrix arm. (B) Mitochondrial membranes from the indicated complex I strains (complemented wild type [cWT], ind1,
nucm, nubm and nukm) were separated by SDS-PAGE. Western blots were labelled with antibodies against Ind1 and the complex I subunits NUBM and NUCM, as
indicated. Antibodies against mitochondrial aconitase, Aco1, were used to confirm equal loading and protein transfer. (C) Mitochondrial membranes were separated by
BN-PAGE. Complex I is shown by in-gel NADH:NBT staining (top panel) and by Western blot analysis with antibodies against NUBM and NUCM. The immunoblots were
exposed for a relatively long time to visualize all assembly intermediates, but short exposure of the NUCM signal of fully assembled complex I is also shown (bottom
panel).
can also be seen in nubm and nukm, but not in cWT, and
likely corresponds to the Q module. Kmita et al. (24) have
previously reported a Q module assembly intermediate in
Y. lipolytica containing the NUCM, NUGM, NUKM and NUFM
subunits. Combined, these subunits would have a molecular
weight of 116.42 kDa (calculated based on molecular weights
in Angerer et al. (28)). Assembly factors would likely also be
bound to this structure, resulting in the observed molecular
weight of ∼160 kDa. These data show that while mitochondrial
membranes of ind1 cells have some fully assembled complex I
and a 500 kDa intermediate, there is accumulation of a Qmodule
intermediate.
Next, we investigated the assembly of complex I in the Ind1
protein variants. Interestingly, the G136D and G285C variants
that have normal complex I levels (Fig. 3A) visibly accumulated
the Q module intermediate containing NUCM (Fig. 5B, lower
panel). Generally, the pattern of assembly intermediates
containing NUCM is similar in all mutants, except that Ind1D103Y
accumulated relatively more Q module intermediate and very
little of the 500 kDa intermediate. For intermediates containing
the NUBM subunit, variants with low levels of complex I
(N271Qfs*31, L102P and D103Y) closely resembled the empty
vector control, whereas those with near normal complex
I levels (G136D, L191F,G285C)more closely resemble cWT (Fig. 5B,
upper panel).
ind1 mutants are sensitive to cold
During storage ofY. lipolytica strains, it was noticed that the ind1
mutant was sensitive to cold, exacerbating the mild growth
defect. To investigate this further, the growth of ind1mutants, as
well as nucm + NUCMY144F, nubm and nukm, was compared
at 28◦C and 10◦C. Using a standard drop assay for yeast growth,
cells were spotted onto agar plates in a dilution series. Each
cell seeds a new colony, the diameter of which is determined
by cell division rate and cell size. After incubation of the plates
overnight at 28◦C plates to initiate growth, they were placed
either at 28◦C for a further 2 days or moved to 10◦C for 10–
14 days. At 28◦C all strains grew similarly, despite slight vari-
ations in colony size (Fig. 6, left panels). However, when grown
at 10◦C, some strains displayed a dramatic growth retardation
(Fig. 6, right panels). The ind1 strain expressing wild-type IND1,
Ind1 variant G136D, nubm and nukm all displayed significant
growth at 10◦C. However, all other Ind1 variants displayed very
slow or no further growth at 10◦C. Interestingly, the nubm and
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Figure 5. Complex I assembly intermediates in Ind1 variants. Mitochondrial
membranes from ind1 cells expressing wild-type IND1 (cWT) and the indicated
protein variants were separated by SDS-PAGE (A) or by BN-PAGE (B). The gels
were blotted and labelled with antibodies against NUBM, NUCM or Sdh2. CBB,
Coomassie Brilliant Blue staining of complex V was used as a loading control.
nukmmutants that lack complex I completelywere able to grow
in cold conditions, but nucm + NUCMY144F with an inactive form
of complex I could not grow, similar to the ind1 mutant.
These data reveal a novel growth difference of certain com-
plex I mutants grown at normal (28◦C) or cold (10◦C) conditions.
Ind1 variants, except for G136D, also display this temperature-
dependent growth defect.
Complex I assembly in the Ind1G285C variant is
temperature sensitive
The Ind1 variant G285C has normal levels and activity of com-
plex I (Fig. 3A). However, it accumulated the Q module inter-
mediate (Fig. 5B), and growth at 10◦C was impaired (Fig. 6). To
investigate if assembly of complex I in the G285C variant is
conditional on temperature, mitochondrial membranes were
isolated from cells producing wild-type Ind1 (cWT) and the Ind1
G285C variant after overnight growth at 10◦C and compared
with samples grown at 28◦C. Mitochondrial membranes were
separated by BN-PAGE and stained with NADH:NBT to assess
formation of complex I. cWT displayed full complex I assembly
in cultures grown at both 28◦C and 10◦C (Fig. 7A). By contrast,
the G285C Ind1 variant could not support complex I assembly
when grown at 10◦C, with complex I levels decreased to those
in the ind1 mutant (Fig. 3A). BN-PAGE followed by Western
blotting and labelling with antibodies against NUBM confirmed
the significant decrease in complex I (Fig. 7A). Immunodetection
of Ind1 showed that the G285C protein variant is stable at 10◦C,
meaning that the decrease in complex I levels is not due to a
cold-dependent degradation of the Ind1G285C protein.
Next, the effect of cold conditions on assembly interme-
diates of complex I was assessed. Mitochondrial membranes
were separated by BN-PAGE followed by Western blotting with
antibodies against NUCM. A short exposure of the signal con-
firmed the decreased levels of fully assembled complex I in
cells expressing the G285C Ind1 variant grown at 10◦C (Fig. 7B,
top panel). A longer exposure revealed a different pattern of
complex I assembly intermediates in mitochondria isolated at
normal and cold temperatures (Fig. 7B). Ind1G285C samples from
cold conditions lacked a band corresponding to the assembly
intermediate at 500 kDa, made up of the N and Q modules,
and an increase in the Q module intermediate at 160 kDa. This
suggests that the G285C Ind1 variant accumulates greater levels
of the Qmodule at cold temperatures, as it is unable to assemble
it into the 500 kDa intermediate. There is still a strong signal
at the size corresponding to complex I; however, this is due to
a long exposure time needed to see assembly intermediates.
Taken together, these data show that the Ind1 G285C variant is
more severely impaired in complex I assembly when grown in
cold conditions.
Discussion
Since NUBPL was associated with mitochondrial disease result-
ing from complex I deficiency (1,11,12), the gene is routinely
included in the list of candidate genes for genetic diagnoses.
In children’s hospitals around the world, additional mutations
have been found in NUBPL that are likely to be pathogenic. In
this study five protein variants of human NUBPL were recreated
in the homologous Ind1 protein in the yeast Y. lipolytica to study
the effect of the amino acid changes on complex I assembly and
to confirm pathogenicity.
Ind1 variants L102P and D103Y showed the strongest
decrease in complex I, similar to the effect of N271Qfs*31
and deletion of the IND1 gene (Fig. 3). The L102P substitution
destabilized the Ind1 protein (Fig. 2), which most likely explains
the complete loss of functionality. The D103Y substitution
does not affect protein stability, suggesting that the amino
acid change renders Ind1 inactive. Asp103 is situated at the N-
terminal end of the Switch I motif (Fig. 1A). In molecular motors
driven by ATP (or GTP) hydrolysis, the Switch I and II sequences
form the nucleotide binding pocket, while a conserved lysine
residue of the Walker A motif interacts with ATP (29). Upon
ATP hydrolysis, Switch I and II undergo large conformational
changes, facilitating monomer–dimer transitions (e.g. in ParA
and MinD in bacterial cell division) or interactions with other
proteins (e.g. NifH in nitrogenase). D103 aligns with D38 in MinD
of Escherichia coli,which is the residue required for dimerization
of MinD as well as for interaction between MinD and MinC
(30). NUBPL and other members of the NBP35/Mrp subfamily of
P-loop NTPases also form dimers (9). Lack of dimer formation
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Figure 6. ind1 mutants are sensitive to low temperature. Growth of ind1 cells expressing wild-type IND1 (cWT) and the indicated protein variants, and complex I
mutants nucm + NUCMY144F, nubm and nukm grown at normal (28◦C) and cold (10◦C) temperatures. e.v., empty vector. Images show serial dilutions of cell cultures
spotted onto agar plates.
or lack of interaction with another protein, for example a
subunit of complex I, is likely to fully abolish the function
of NUBPL/Ind1. Interestingly, the Ind1D103Y variant appears to
have a block in assembling the N module onto the Q module,
as very little matrix arm assembly intermediate was observed
and high levels of Q module accumulated (Fig. 5B). Possibly, a
failure to use ATP hydrolysis for conformational changes of
Ind1 may have a dominant effect and trap a specific assembly
intermediate.
The Ind1L191F variant caused a moderate decrease in complex
I levels and activity. This residue is close to the Mrp family
signature (Fig. 1A) found only in the subfamily of NBP35/Mrp P-
loop NTPases. Members of this subfamily are found in archaea,
bacteria and eukaryotes. The precise molecular function of this
amino acid motif is not known.
The G136D substitution in Ind1 had no significant effect
on complex I levels and redox activities (Fig. 3); however, the
variant protein caused accumulation of the Q module assembly
intermediate, albeit at low levels (Fig. 5). The equivalent G138D
variant in human NUBPL has so far not been associated with
a clinical case of complex I deficiency even though it is found
at ∼5-fold higher frequency (Table 2) than the L104P variant (to
date, the most frequent complex I deficiencymissense mutation
that has been found). Both G138D and c.815-27T>C variants have
been observed in the heterozygous state in Parkinson’s disease
patients (P. Eis and E.Hatchwell, personal communication), albeit
not at a significantly higher frequency compared with pub-
licly reported subjects (gnomad.broadinstitute.org). Since the
allele frequency for G138D and c.815-27T>C aremoderately high
(Table 2), homozygotes or compound heterozygotes for these
variants are likely to exist, and they may have late onset symp-
toms linked to mild complex I deficiency that are clinically
relevant in diseases involving mitochondrial dysfunction, such
as Parkinson’s disease, as suggested by others (15,31).
It is possible that in the case of ‘mild’ IND1mutations, effects
on complex I assembly only manifest themselves under certain
conditions, as for the Ind1 G285C variant. At the normal growth
temperature of Y. lipolytica (28◦C), there was no significant effect
on complex I levels and activities, although accumulation of the
Q module assembly intermediate was observed (Fig. 5). At low
temperature (10◦C), the Ind1 G285C variant showed a dramatic
decrease in complex I and increased levels of the Q module
intermediate (Fig. 7). Glycine 285 is located at the end of two
short alpha helices (Fig. 1C), and a cysteine may disrupt this
structure. Alternatively, the cysteine, if exposed, may form an
unwanted disulfide bridge with another cysteine, in particular
the cysteines of the CxxC motif, which are important for the
function of NUBPL/Ind1 (8,10). A Gly to Cys substitution inNfu1, a
mitochondrial protein involved in FeS cluster assembly that also
carries a CxxC motif, causes a dominant genetic effect in yeast
(32) and severe mitochondrial disease in humans (33). Why the
effects of G285C are exacerbated at cold temperatures remains
an open question.
At the normal growth temperature of 28◦C, Y. lipolytica
containing Ind1 variants and complex I mutants grew sim-
ilarly to cWT, because NADH oxidation in these strains is
maintained by expression of ND2i, a single subunit NADH
dehydrogenase on thematrix side.However, at 10◦C, functionally
compromised Ind1 variants and nucm + NUCMY144F displayed
almost no growth, whereas the nubm and nukmΔ strains
were comparable with cWT in cold tolerance (Fig. 6). An
initial hypothesis for this difference is that strains with a
non-functional complex I produce large amounts of reactive
oxygen species (ROS) such as superoxide (5), which may be
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Figure 7. The Ind1 G285C variant cannot assemble complex I at low temperature.
(A) Complex I levels in mitochondrial membranes from ind1 expressing wild-
type IND1 (cWT) or Ind1G285C following growth at 28◦C or 10◦C. Complex I was
visualized by BN-PAGE and NADH:NBT staining and by Western blotting with
antibodies against NUBM. The levels of Ind1, NUCM and NUBM were assessed
by standard SDS-PAGE and Western blot analysis. Ponceau S staining was used
to confirm equal loading and transfer. (B) Complex I assembly intermediates
containing the NUCM subunit from samples as in (A) were detected by Western
blot analysis of BN-PAGE gels. Top panel, short exposure; bottom panel, long
exposure.
exacerbated in the cold. Interestingly, lack of the accessory
NDUFS4 subunit of complex I in themodel plant Arabidopsiswas
associated with increased ROS production and diminished cold
tolerance (34). The nukmΔ mutant lacks complex I completely,
and the nubm lacks the FMN site where most ROS is produced.
Further investigation is needed to uncover the cause of this
growth defect.
In summary, of the five NUBPL missense variants that were
functionally assessed in Y. lipolytica, four (L104P, D105Y, L193F
and G285C) were found to be deleterious to complex I and
one (G138D) was found to exhibit a mild defect. Along with
other studies (18,21,35,36), these results reconfirm the utility
of Y. lipolytica as a model for human mitochondrial disorders.
However, care must be taken in over-interpreting the results, as
some effects seen in Y. lipolytica have not been found in humans.
In human NUBPL RNAi HeLa lines, the levels of NDUFV1 subunit
are substantially decreased (10), whereas in the Y. lipolytica
ind1 mutant, the levels of the homologous NUBM protein are
only slightly less than in cWT. Secondly, the Ind1D103Y variant
appears to have stable protein levels in Y. lipolytica, but human
patients with D105Y have almost no NUBPL protein (11). Ideally,
all clinically relevant NUBPL mutations should also be tested in
human cell lines, although Y. lipolytica is useful as a cost-effective
model to study potentially pathogenic mutations affecting
complex I.
A defect in Q module assembly in Y. lipolytica ind1 mutants
is consistent with studies of NUBPL in human cell lines (10,11).
The Qmodule has 3 FeS clusters thatmay be specifically inserted
by NUBPL. However, detailed proteomic analysis of complex I
assembly intermediates did not find NUBPL associated with
any subcomplexes; it only occurred as a dimer (37). Possibly,
NUBPL interacts with an individual Q module subunit, or the
protein interaction with the Q module assembly intermediate
is transient. The Ind1 protein variants characterized in this
study, in particular the D103Y variants, could serve as a tool to
unravel exactly which step in complex I assembly is mediated by
NUBPL/Ind1.
Materials and Methods
GenBank Accession Numbers
NUBPL, Homo sapiens: NG_028349.1; NP_079428.2
Ind1, Yarrowia lipolytica: XP_501064.1
Yeast strains and growth
The Y. lipolytica ind1 strain in the GB10 genetic background
(ura3-302, ind1::URA3, leu2-270, lys11-23, NUGM-Htg2, NDH2i,
MatB) was used to analyze mutant versions of IND1 and has
been described previously (8). The IND1 gene (YALI0B18590g)
including its native promoter (1 kb upstream of the ATG) was
reintroduced using the pUB4 plasmid (23) with a hygromycin
selection marker, HygB from Klebsiella pneumoniae, to obtain the
complemented wild type (cWT). The nubm, nucm, nucm +
NUCMY144F and nukm were as previously described (18,25,38)
but transformed with ‘empty’ pUB4 plasmid to grow the cells in
the presence of hygromycin. Y. lipolytica cells were grown in rich
medium containing 1% (w/v) yeast extract and 1% (w/v) glucose
(Y1/2D), either in liquid culture or on solid mediumwith 2% (w/v)
agar. Hygromycin B (75 μg ml-1) was added for selection of cells
transformed with the pUB4 plasmid.
Molecular cloning and mutagenesis
The IND1 sequence from pUB4-IND1-strep (8) was cloned into
the pGEM-T Easy vector (Promega, Madison, WI USA) and used
for mutagenesis using a QuikChange® II kit (Agilent, Santa
Clara CA, USA), as per the manufacturer’s instructions. Muta-
genesis primers were designed using the online QuikChange
primer design tool, hosted at http://www.genomics.agilent.com/
primerDesignProgram.jsp (Table S2). Mutated IND1-strep
sequence was inserted into pUB4, between XbaI and NsiI
restriction sites. Plasmids were confirmed by sequencing and
diagnostic restriction digest.
Y. lipolytica cells were transformed as described (39). Briefly,
cells were grown overnight in YP1/2D (1% (w/v) yeast extract, 2%
(w/v) peptone and 1% (w/v) glucose, at 28◦C,and collected by cen-
trifugation, or alternatively harvested from a fresh YP1/2D plate.
Cells were resuspended in 100 μl buffer [45% (w/v) polyethylene
glycol 4000, 0.1 M lithium acetate pH 6.0, 0.1 M dithiothreitol,
250 μgml-1 single-stranded carrier DNA] and 200–500 ng plasmid
was added. The mixture was incubated at 39◦C for 1 h and then
spread on a YP1/2D plate containing 75 μg ml-1 Hygromycin B.
Transformants were visible after 2–3 days growth at 28◦C.
Recombinant protein expression
IND1 sequences encoding the Ind1 variants L102P and D103Y,
excluding the first 36 amino acids, were cloned from pUB4 into
pET15b. Ind1-strep was expressed and purified as described
in Bych et al. (8). Briefly, plasmids were transformed into
E. coli Rosetta containing a plasmid with the genes for iron–
sulfur cluster assembly (pISC) and plasmidpLYS. Colonies were
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grown overnight at 37◦C in Lysogeny broth (LB) media, with
required antibiotics, and then diluted 50× in 100ml Terrific broth
[47.6 g l-1 Teriffic broth, 0.8 ml 50% (v/v) glycerol] and grown until
OD600 = 0.6. Protein expression was induced by addition of 1 ml
l-1 benzylalcohol, 50 μm Fe–ammonium citrate, 100 μm L-cysteine
and 1.2ml l-1 isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells
were grown at 20◦C overnight, then harvested by centrifugation
at 5000 × g and flash frozen in liquid nitrogen. Cells were then
resuspended in buffer W (100 mm Tris–HCl pH 8.0, 150 mm NaCl)
with 0.2% (w/v) dodecyl maltoside. The cell suspension was
sonicated and separated into soluble and insoluble fractions by
centrifugation at 16100 × g.
Blue-Native Polyacrylamide Gel Electrophoresis
Unsealed mitochondrial membranes were isolated as published
(17), with minor modifications. Briefly, Y. lipolytica cells from
0.5 l overnight culture were harvested by centrifugation at
3500 × g. Pellet weights were typically between 2–8 g. Cells
were washed with dH20. Per gram cells, 2 g fine glass beads,
2 mm PMSF and 2 ml ice cold mito-membrane buffer (0.6 M
sucrose, 20 mm MOPS–NaOH, pH7.5, 1 mm EDTA) were added.
Cells were disrupted by 15 rounds of 1 min vortexing and 1
min incubation in ice. Differential centrifugation was performed
at 3500 × g for 10 min and 40000 × g for 120 min at 4◦C.
Pellets were resuspended in mito-membrane buffer and stored
at -80◦C. For BN-PAGE, unsealed mitochondrial membranes
were mixed with solubilization buffer [750 mm aminocaproic
acid, 50 mm Bis-Tris–HCl pH 7.0, 0.5 mm EDTA, 1 % (w/v)
dodecyl maltoside] and incubated on ice for 5 min followed by
centrifugation at 16100 × g, at 4◦C, for 10 min. The supernatant
containing solubilized membrane proteins were diluted to 0.25
μg μl-1 protein (Bradford assay) with solubilization buffer and
0.25% (w/v) Coomassie G250. Typically, 6.25 μg protein was
loaded per lane. 5 μl NativeMarkTM was used as a molecular
weight marker. All BN-PAGE performed used NativePageTM 4–
16% Bis-Tris gels (Invitrogen, Waltham, MA USA), with 1 mm
spacers. The anode buffer was 50 mm Bis-Tris–HCl, pH7.0;
cathode buffer was 50 mm Tricine, 15 mm Bis-Tris–HCl, pH7.0.
Gels were run in a XCell SureLockTM system (Thermo Fisher
Scientific, Waltham, MA USA) at 4◦C, for the first 45 min at
100 V (max 10 mA) with cathode buffer containing 0.02% (w/v)
Coomassie G250, then for ∼2.5 h at 250 V (max 15 mA) with
cathode buffer containing 0.002% (w/v) Coomassie G250, until
the dye front exited the bottom.
BN gels or PVDF membrane were stained in Coomassie solu-
tion [45% (v/v) MeOH and 5% (v/v) acetic acid, 0.05% Coomassie
R250] for 1–12 h.Gels were destained using a solution of 45% (v/v)
methanol and 5% (v/v) acetic acid.
Protein blot analysis
Mitochondrial membranes were mixed with Laemmli buffer [2%
(w/v) SDS, 125 mm Tris–HCl pH 6.8, 10% (w/v) glycerol, 0.04%
(v/v) β-mercaptoethanol, and 0.002% (w/v) bromophenol blue]
and separated on a 15% SDS-PAGE gel. Proteins were trans-
ferred under semi-dry conditions to nitrocellulose membrane
(ProtranTM). Equal loading and transfer was confirmed using
Ponceau S stain. Proteins were labelled with antibodies and
detected using secondary horseradish peroxidase-conjugated
antibodies and chemiluminescence. Mouse monoclonal anti-
bodies against the NUBM and NUCM subunit complex I were
a gift from Volker Zickermann. Rabbit polyclonal antibodies
against Sdh2 and Aco1 were raised against recombinant Sac-
charomyces cerevisiae proteins and previously reported (40); anti-
bodies against Y. lipolytica Ind1 are described in Bych et al. (8).
Protein was transferred from the BN-PAGE gel to a PVDF
membrane (0.2 μm, MilliporeTM) using wet transfer and BN
cathode buffer, for 600 min at 40 mA (maximum voltage
100 V). After transfer, immunolabelling was carried out as
described above.
NADH dehydrogenase assays
BN gels were stained for complex I, as described in Sabar et al.
(24). Briefly, BN gels were equilibrated in 0.1 M Tris–HCl pH 7.4
and then incubated with new buffer containing 0.2 mm NADH
and 0.1% (w/v) NBT. After the desired staining intensity was
reached, the reaction was stopped using a solution of 45% (v/v)
MeOHand 5% (v/v) acetic acid.Destaining using a solution of 45%
(v/v) MeOH and 5% (v/v) acetic acid was performed for optimal
enzyme stain visualization.
NADH:HAR oxidoreductase activity was assayed as described
(8). Activity for 25 μg mitochondria was measured in a 1 ml
volume of 20mmHEPES–NaOHpH 8.0, 2mmNaN3, 0.2mmNADH,
2 mm HAR and 40 μg ml-1 alamethicin. Measurements were
made in a 1-ml quartz cuvette using aUV/Vis spectrophotometer
(Jasco, V-550) and started after addition of HAR.
dNADH:DBQ oxidoreductase activity was measured as
dNADH oxidation activity in the presence of the ubiquinone
analogue n-decylubiquinone (DBQ) as an electron acceptor.
Activity for 50 μg mitochondria was measured in a 1 ml volume
of 20 mm MOPS–NaOH pH 7.4, 50 mm NaCl, 2 mm KCN, 0.1 mm
dNADH and 0.1 mm DBQ. Measurement started after addition
of DBQ. 0.01 mm of the complex I inhibitor Piericidin A was
added at the end of the reaction to ensure that dNADH:DBQ
oxidoreductase activity is due to complex I.
Supplementary Material
Supplementary Material is available at HMG online.
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